Trial Profile
Randomized Phase II Study of Ixabepilone Plus Trastuzumab vs. Docetaxel Plus Trastuzumab in Female Subjects With Her2+ Locally Advanced and/or Metastatic Breast Cancer. [Estudio fase II de Ixabepilona y Trastuzumab versus Docetaxel y Trastuzumab en mujeres con cáncer de mama localmente avanzado y/o mestatásico con sobresexpresión de Her2]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Ixabepilone (Primary) ; Docetaxel; Trastuzumab
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 10 Mar 2012 The trial status is recruiting in (Spain and France) and prematurely ended in (Italy) as reported by European Clinical Trials Database.
- 02 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Feb 2012 Actual patient number 50 added as reported by ClinicalTrials.gov.